Replies to post #120592 on Biotech Values

[DewDiligence]

VRUS/BMY add 12-week arms to study of PSI-7977 + BMS-790052, including two arms testing Incivek/Victrelis failures:

http://finance.yahoo.com/news/New-12-Week-InterferonFree-prnews-3892030583.html?x=0&.v=1

There are four news arms, all for genotype-1 patients. Two new arms in the first-line setting test PSI-7977 + BMS-790052 for 12 weeks with or without ribavirin.

Two new arms in the second-line setting following failure on Incivek or Victrelis test test PSI-7977 + BMS-790052 for 12 weeks with or without ribavirin.

PSI-7977 is a nuke from VRUS and BMS-790052 is an NS5A inhibitor from BMY.